PARALLEL SESSION 31 – PHARMA 2

ID 92. LONGITUDINAL CHANGES IN PHYSICIANS’ PRACTICES ON PROCEDURAL PAIN MANAGEMENT IN NEONATES. A SURVEY CONDUCTED AT TWO TIME POINTS, 20 YEARS APART

Medical Doctor Eleni Agakidou1, Medical Doctor Aggeliki Kontou1, Medical Doctor Maria Farini1, Medical Doctor Theodora Stathopoulou1, Medical Doctor Agathi Thomaidou1, Medical Doctor Konstantina Tsoni1, Associate Professor Paraskevi Karagianni1, Professor Kosmas Sarafidis1
1Ippokrateion General Hospital/ Aristotle University Of Thessaloniki, Thessaloniki, Greece

Background: Neonates receiving intensive care are exposed to numerous painful and stressful procedures, which may have serious acute and long-term consequences. The aim of this survey was to investigate whether Greek physicians working in neonatal intensive care units (NICUs) have changed their practices on neonatal pain management, as consequence of the knowledge emerged during the last decades. Methods: Anonymous questionnaires were distributed to 117 and 145 physicians working in NICUs all-over Greece in the years 2000 and 2019, respectively. Results: Response rate was 90.6% and 80.7% in 2000 and 2019, respectively. All respondents, at both time-points, believed that neonates experience pain, which has serious consequences, while a higher proportion of the 2019-respondents believed that procedural pain should be effectively treated (90% vs. 99%, p=0.015). Utilization of NICU protocols and pain assessment tools remained low despite the significant increase over-time. Regarding prolonged pain, the use of systemic A-S during mechanical ventilation increased (p<0.001) by 2019, while remaining comparably high (71 vs. 79%) during chest drainage. Regarding acute procedural pain, the proportion of physicians using systemic analgesia for endotracheal intubation remained stable (50%), while tended lower over-time for the other procedures. The use of local analgesia significantly decreased by 2019, while the application of sweet solutions and non-pharmacological measures significantly increased. Opioid implementation significantly increased, with a shift from morphine to fentanyl. International literature and perinatal-neonatal congresses were stated as the main sources of updating physicians’ knowledge. Conclusion: The beliefs of Greek physicians working in NICUs as to neonates’ capability to experience pain/stress and the need for effective prevention and treatment, remained strong during the past 20 years. Despite the increased awareness on the importance of providing adequate A-S in sick infants and overall improvement in pain management, every day practices on pain management are still suboptimal. Steps that need to be taken to further improve management of neonatal procedural pain should include continuing medical education and implementation of globally accepted, evidence-based protocols, integral part of which should be -apart from pharmacological and non-pharmacological measures- the use of readily applied and reliable tools for assessment of acute or prolonged pain/stress.

None
ID 468. Population pharmacokinetics of fentanyl in very preterm infants

Miss Maddie Bardol1, Dr. Vineta Fellman2,3, Dr. Elisabeth Norman3, Dr. Joseph Standing1
1Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London (UCL), London, United Kingdom, 2Children’s Hospital, University of Helsinki, Helsinki, Finland, 3Department of Clinical Sciences, Pediatrics, Lund University and Skåne University Hospital, Lund, Sweden

Background: Fentanyl is a synthetic opioid widely used in neonatal intensive care unit, however its optimal dose has not been determined in preterm infants. The aim of this work was to develop a population pharmacokinetic model for a new formulation of fentanyl 5 μg/mL in preterm infants and test the influence of genetic variants (SNPs) on the PK.

Methods: This PK/PD/PG study is part of a PK/PD/PG study designed to optimize fentanyl dosage for procedural pain in newborn preterm infants. 25 infants received 0.5 μg/kg before skin-breaking procedures or 2 μg/kg before tracheal intubation. The median gestational age and weight were 27 weeks and 0.85 kg, respectively.

Population pharmacokinetic modelling was undertaken with NONMEM 7.4. Body weight and postmenstrual age (PMA) were included in the model using an allometric weight scaling and a sigmoidal maturation function, respectively. To test the influence of 153 SNPs on the clearance (CL), a screening process was first done using multiple linear regression with Plink 1.9. The SNPs selected were then tested as categorical covariates in the PK model using NONMEM 7.4.

Results: A two compartment model provided the best fit. The estimates of the PK parameters (standardized to 70 kg) were: CL = 69.9 7 L/h (CV 8%), central volume of distribution = 174 L (CV 12%), peripheral volume of distribution = 15.6 L/h (CV 23%), and inter-compartmental clearance = 5.6 L/h (CV 34%). The allometric weight exponent was fixed to 0.75 for CL and 1 for volumes. The parameters of the maturation function were fixed to values previously published. The model showed that 3 SNPs induced a significant increase of the CL: rs111517339 T/TA coding for the receptor ATP Binding Cassette Subfamily C Member 1 (ABCC1) and rs11079921 T/C as well as rs8077268 C/T coding for ABCC3.

Conclusion: A population PK/PG model was successfully developed to describe the fentanyl concentration in preterm infants. The CL in this population was affected by PMA and weight. The study shows that SNPs coding for ABCC1 and ABCC3 receptors explain a part of the variability of the fentanyl elimination.

None declared
ID 28. INCREASED NEONATAL MORBIDITY AFTER INTRAUTERINE EXPOSURE TO ANTIPSYCHOTICS

Doctor Essi Whaites Heinonen, Doctor Lisa Forsberg, Doctor Ulrika Nörby, Ass.Prof. Katarina Wide, Prof. Karin Källén

Department of Neonatology, Karolinska University Hospital, Stockholm, Sweden, Department of Pediatrics, Division for Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden, Department of Emergency Pediatrics, Karolinska University Hospital, Stockholm, Sweden, Department of E-health and Strategic IT, Health and Medical Care Administration, Stockholm Healthcare Region, Stockholm, Sweden, Centre of Reproduction Epidemiology, Tornblad Institute, Department of Clinical Sciences, Lund University, Lund, Sweden

BACKGROUND
Use of antipsychotic drugs during pregnancy has more than doubled in Sweden in the last decade. Antipsychotic drug exposure during pregnancy is associated with increased neonatal morbidity, with especially CNS-symptoms being warned of by both the American Food and Drug Administration and the European Medicines Agency. However, the severity of the symptoms and to what extent they are caused by the medication or the underlying disease is hard to approach with studies and still somewhat unclear and debated.

METHODS
The study was a register-based study on prospectively collected data, combining data from the Swedish Medical Birth Register (MBR), the Prescribed Drug Register (PDR), the Swedish Neonatal Quality Register (SNQ), and the Perinatal Revision South Register (PRS). The study population consisted of all singleton births in Sweden, a total of 1,307,487 infants, registered in the MBR between July 1, 2006, and December 31, 2017. Exposure of an antipsychotic drug (ATC-code N05A except for lithium and the antipsychotics used as antiemetics) was defined as a prescription registered in the PDR during or 1 month before pregnancy and/or self-reported use registered in the MBR. Late pregnancy exposure was defined as a prescription filed in the last three months of pregnancy. Risk ratios (RR) were calculated for admission to neonatal care, the main outcome, and for the separate neonatal morbidities.

RESULTS
Crude RR for admission to neonatal care after intrauterine exposure to antipsychotics was 2.17 (95% CI 1.94-2.43) and for exposure during late pregnancy 2.73 (95% CI 2.45-3.04) when compared with the general population. The risk increase was lower but stayed significant after adjustment for parity, maternal age, BMI, smoking and concomitant medication and when compared with children to women treated with antipsychotics before or after but not during pregnancy. The incidence of several neonatal morbidities such as respiratory disorders, jitteriness and hypoglycemia was significantly increased amongst children exposed to antipsychotics. (Table 1)

CONCLUSION
Our results support a strong correlation between intrauterine exposure to antipsychotics and the need of specialized neonatal care. The risk is largest after use of antipsychotics in late pregnancy.
ID 407. Determination of endocrine disruptors levels in human milk and risk assessment of neonatal exposure

Ass. Professor Eleftheria Hatzidaki¹, Katerina Kalli­giannaki¹,², Ioanna Katsikantami², Nikola­na Anagnostatou³, Vasiliki Karzi², Elena Vakonaki², Ass. Prof. of Toxicology Manolis Tzatzarakis², Prof. of Toxicology Aris­tidis Tsatsakis²

¹Dept. of Neonatology and NICU, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece, ²Laboratory of Toxicology Science and Research, Medical School, University of Crete, Heraklion, Greece

Background: The benefits of breastfeeding for the immune system, growth and health status later in life, are widely known. However, maternal exposure to pollutants, such as pesticides, parabens and bisphenol A can result in breast milk contamination and infant exposure. Exposure to endocrine disruptors during development, beginning from the fetal period until puberty, may cause harmful health effects for human. The aim of this study was to estimate the burden of human milk from Cretan women with methyl, ethyl, propyl, butyl and benzyl parabens, bisphenol A, bisphenol analogues F and S, triclosan and triclocarba­m and the risk assessment of neonatal exposure.

Methods: Fifty-three milk samples (5 ml) were treated with phosphoric acid and hydrolyzed with b-glycuronidase/b-glycuronidase sulfate (50°C, 4hrs) and extracted with acetonitrile (7.5 ml) with salts addition (MgSO₄, sodium citrate tribase/dibase, NaCl). Clean up of the supernatant was performed with PSA and MgSO₄. Organic phase was dried, reconstituted to acetonitrile and injected in LC-MS with an APCI ionization source.

Results: The method was linear (R²> 0.992), accurate (range: 86.4% to 109.2%) and precise (%RSD range: 4.3 to 22.6) and provided low detection limits (from 0.01 to 0.04 ng/ml). The mean concentrations for parabens ranged from 0.47±0.60 (butyl) to 3.53±9.60 ng/ml (ethyl), for bisphenol S and A were 0.42±0.43 and 0.37±0.83 ng/ml, respectively, and 3.05±7.23 ng/ml for triclosan. Methyl paraben was the most frequently detected compound (95.7%) among parabens, followed by propyl (74.5%), ethyl (40.4%), benzyl (31.9%) and butyl (21.3%). Triclosan, bisphenols A and S were detected in 93.6, 63.8 and 10.6% of the samples, respectively. The hazard index (HI) was calculated for risk assessment based on the detected levels of each analyte, the daily milk consumption per infant weight and reference limits for safe exposure. The mean calculated HI values were lower than 0.1 for all analytes.

Conclusion: The findings indicate that the compounds are detectable in human milk at low levels. The risk assessment approach showed that exposure is safe for newborns (HI<1). Despite the presence of these contaminants in human milk, the benefits of the breastfeeding are still impressive.

None declared